ArticleDiscover oncology2023
Dynamic estimates of survival in oncocytic cell carcinoma of the thyroid.
Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Epidemiology and prognostic factors of Hürthle-oncocytic cell carcinoma of the thyroid.Discover oncology · 2026Article
- Conditional survival and prognostic nomogram for distant metastatic differentiated thyroid cancer after total thyroidectomy.Scientific reports · 2026Article
- Designing a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.Discover oncology · 2025Article
- Survival benefits in non-small cell lung cancer during the immune checkpoint inhibitor era: integrating lymph node burden for prognostic precision.Translational lung cancer research · 2025Article
- Trends in incidence, mortality, and conditional survival of anaplastic thyroid cancer over the last two decades in the USA.Frontiers in endocrinology · 2025Article
- Conditional survival and changing risk profile in patients with gliosarcoma.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLittle is known about death hazard and conditional survival of oncocytic cell carcinoma of the thyroid (OCC).
methodsPatients diagnosed with OCC between 2004 to 2019 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to estimate the actuarial disease-specific survival (DSS). The annual hazard rate of death was depicted employing the hazard function. Based on the life-table method, the conditional DSS was calculated.
resultsIn terms of DSS rates, there were statistically significant differences among the different stages (P < 0.01). Annual hazard curves for mortality from OCC in the entire study participants demonstrated an overall decreasing tendency with two peaks at 3 and 10 years. In patients with distant disease, the death risk curve was the steepest and decreased quickly and evidently. Conditional DSS tended to increase over time in the entire study population. Patients with distant disease showed more significant alterations than those patients with local or regional disease.
conclusionsPrognosis improved over time in patients with OCC. The largest increase in conditional DSS was observed in patients with distant disease. Conditional survival may provide more relevant prognostic information than conventional survival estimates and allow personalized follow-up and counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.